- Home
- IPA vs ANTX Comparison
IPA vs ANTX Comparison
Compare IPA & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- ANTX
- Stock Information
- Founded
- IPA 1983
- ANTX 2017
- Country
- IPA United States
- ANTX United States
- Employees
- IPA 101
- ANTX N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- IPA Health Care
- ANTX Health Care
- Exchange
- IPA Nasdaq
- ANTX Nasdaq
- Market Cap
- IPA 46.0M
- ANTX 33.2M
- IPO Year
- IPA 2017
- ANTX 2022
- Fundamental
- Price
- IPA $1.11
- ANTX $1.08
- Analyst Decision
- IPA Strong Buy
- ANTX Buy
- Analyst Count
- IPA 2
- ANTX 3
- Target Price
- IPA $4.00
- ANTX $2.00
- AVG Volume (30 Days)
- IPA 4.8M
- ANTX 351.5K
- Earning Date
- IPA 07-28-2025
- ANTX 08-12-2025
- Dividend Yield
- IPA N/A
- ANTX N/A
- EPS Growth
- IPA N/A
- ANTX N/A
- EPS
- IPA N/A
- ANTX N/A
- Revenue
- IPA $16,581,105.00
- ANTX N/A
- Revenue This Year
- IPA $4.67
- ANTX N/A
- Revenue Next Year
- IPA $14.15
- ANTX N/A
- P/E Ratio
- IPA N/A
- ANTX N/A
- Revenue Growth
- IPA 1.34
- ANTX N/A
- 52 Week Low
- IPA $0.27
- ANTX $0.87
- 52 Week High
- IPA $1.15
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- IPA 78.39
- ANTX 43.88
- Support Level
- IPA $0.82
- ANTX $1.07
- Resistance Level
- IPA $1.04
- ANTX $1.11
- Average True Range (ATR)
- IPA 0.14
- ANTX 0.05
- MACD
- IPA 0.03
- ANTX 0.00
- Stochastic Oscillator
- IPA 93.75
- ANTX 8.33
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.